Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, and Biosimilars and Bioanalytical Methods.
Web-Based Cognitive Rehabilitation for Patients With Aggressive Lymphoma With Perceived Cognitive Impairment: A Randomised Pilot Study.
Glofitamab monotherapy in patients with Richter's transformation: safety and efficacy from a phase 1 study.
Choosing between Nivo-AVD and BrECADD: Hodgkin lymphoma's new era.
Bispecific antibody combination therapies in diffuse large B-cell lymphoma.
The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy.
Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries.
Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.
Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapy.
Enterocolitis associated with glofitamab-First report and clinicopathological findings in three cases.
Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma.
Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Data from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
Supplementary Figure S2 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Supplementary Figure S3 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Supplementary Figure S1 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Supplementary Figure S4 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Supplementary Data Figures from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
Supplementary Tables S1-S11 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Supplementary Figure S5 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Conference: International Congress for Neuroethology 2026 - Travel Support Grant
Neural Basis of Sun-Compass Navigation
Motor Control of Flight Maneuvers
Mechanisms of celestial navigation in Drosophila
Mechanisms of celestial navigation in Drosophila
Novel methods for the analysis of animal movement: spatial and temporal structure across scale SCIB conference; Charleston SC; Jan 3-7, 2012
Collaborative Research: Computational Analysis of Maneuvering Flight
FIBR: How Do Brains Regulate Simple Motor Actions to Generate Complex Behaviors?
Aerodynamic Mechanisms of Animal Flight
The Integration of Flight Behavior
Neural Circuitry and Aerodynimcs of Flight Control
Neural Circuitry and Aerodynimcs of Flight Control